Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory Patent applications |
Patent application number | Title | Published |
20150175510 | Method for Preparing High-Content Zeaxanthin - The invention discloses a method for preparing high-content zeaxanthin. In the conventional preparation methods, some methods adopt certain toxic organic solvents; some methods require the multi-step crystallization process; and some methods are featured by long reaction time, high temperature and lower product yield, thus being not suitable for industrial production. The invention adopts lutein crystal or its fatty acid ester as the raw material and utilizes isomerization reaction to produce zeaxanthin, and is characterized in that a mixed catalyst consisting of an organic base catalyst and a cocatalyst is used in the isomerization reaction, wherein the cocatalyst is palladium carbon. The invention has the advantages of simple process route, low reaction temperature, short reaction time, good product purity and high yield, thus being suitable for industrial production, and no poisonous and harmful organic solvent residues in the product, thus being suitable for the use as a food additive or drug. | 06-25-2015 |
20140220120 | CRYSTAL ENTECAVIR, CRYSTAL ENTECAVIR FORMULATION AND METHODS FOR THE PREPARATION THEREOF - The present invention relates to a pharmaceutical composition for treating hepatitis B virus infection comprising crystalline entecavir as the pharmaceutically active ingredient and one or more pharmaceutically acceptable excipients. The tablet and capsule of the pharmaceutical composition have improved stability compared to that of amorphous entecavir under the conditions of light, high temperature and high humidity. | 08-07-2014 |
20140024827 | LINEZOLID INTERMEDIATE AND METHOD FOR SYNTHESIZING LINEZOLID - Provided are a linezolid intermediate and the preparation method thereof and a method for synthesizing linezolid. The structure of the intermediate is shown as formula F2, wherein the compound is prepared by a condensation reaction of (S)—N—(3-chloro-2-hydroxy-1-propyl) acetamide and the compound shown in formula F4. In the preparation methods of the compound shown in formula F2 and linezolid, the reaction system is mild, side reactions are few and the product yield is high. | 01-23-2014 |
20120330048 | Lycopene Intermediate 1, 3, 6, 10-Tetra-Double Bond Pentadec-Carbon Phosphonate as well as Preparation Method and Use Thereof - The invention relates to a novel important lycopene intermediate 3,7, 11-trimethyl-1,3,6,10-tetraene-dodecyl diethyl phosphonate. A current lycopene intermediate 2,4,6,10-tetra-double bond pentadec-carbon phosphonate is difficult to synthesize. The invention provides a novel intermediate, which has the following synthesis steps of: preparing 2,6,10-trimethyl-3,5,9-undecane triene-1-aldehyde from pseudoionone; preparing 2,6,10-trimethyl-2,5,9-undecane triene-1-aldehyde from the 2,6,10-trimethyl-3, 5,9-undecane triene-1-aldehyde; and subjecting the 2,6,10-trimethyl-2,5,9-undecane triene-1-aldehyde and tetraethyl methylenediphosphonate to condensation reaction to obtain target product. The invention can generate novel intermediate from raw material pseudoionone only by four reactions, thus the reactions are easy to control and great industrial value are achieved. | 12-27-2012 |
20120296126 | Preparing Method for Xanthophyll Crystals with Higher Content of Zeaxanthin from Plant Oleoresin - The invention makes public a preparing method for xanthophyll crystals with higher content of zeaxanthin from plant oleoresin. The current methods generally are to get quite pure crystal forms of xanthophyll or zeaxanthin, and they refer to several separation steps. The invention mixes the xanthophyll diester-containing plant oleoresins and food grade alcohol solvents to form even solution, and then soap-dissolve the solution under an alkaline environment; then replenish organic solvents and emulsifiers into the reaction solution and drop some alkali solution into the solution to make partial xanthophyll crystals be transformed to be zeaxanthin through epimerization reaction; after the reaction is finished, add the mixed solvents of alcohol solvent and water to separate out the crystals; use the method of centrifugation or filtration to get the crystals; wash the crystals several times with the mixed solution of deionized water and alcohols to remove the impurities among the crystals; recrystallize the gained crystals with absolute ethyl alcohol, and then dry the crystals to get the products. The invention can gain mixture crystals that contain xanthophyll and zeaxanthin at one time in quite high collection rate, and it is convenient for the followed product application. | 11-22-2012 |
20120065406 | Improved Preparation Method for D-Biotin - The invention discloses the improved preparation method for D-Biotin. If the composite method takes the malonic acid diester as the raw material, the finial biotin will be generated with impurities. The features of the invention refers to the improved preparation method for D-Biotin includes: firstly, (3aS,4S,6aR)-1,3-dibenzyl-4-(ω,ω,ω-3 -alkoxycarbonyl bytyl)-4H-1H-thiophene[3,4-d]iminazole-2,4(1H)-ketone is got after the methane tricarboxylic acid trialkyl ester and (3aR,8aS,8bS)-1,3-dibenzyl-2-oxo-10H-iminazole[3,4-d]thiophene[1,2-a]sulfuryl halide have the condensation reaction in the alkaline environment and then D-Biotin can be got after the reaction process of hydrolysis, decarboxylation and closed loop. The invention succeeds in greatly improving the biotin quality from the original basis and simultaneously avoids the generation of impurities and the occurrence of side reaction. | 03-15-2012 |
20100221323 | Crystal Entecavir Formulation And The Preparation Method Thereof - The present invention relates to a pharmaceutical composition for treating hepatitis B virus infection, comprising the crystal entecavir as pharmaceutically active ingredients and pharmaceutically acceptable excipients. The tablet and capsule of the pharmaceutical composition have more stronger stabilization than that of amorphous entecavir under conditions of lighting, high temperature and high humidity. | 09-02-2010 |